Minocycline Improves the Efficacy of EGFR Inhibitor Therapy: A Hypothesis.

Front Oncol · 2016 · PMC5081343 · PMID 27833902

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Interestingly, the recently published Pan Canadian Rash trial ( 16 ) on the use of minocycline in the management of skin rash caused by erlotinib in lung cancer showed a trend toward improved survival associated with the early use of minocycline (7.6 and 8 months in prophylactic and reactive use) versus if used only when severe rash appears (6 months).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.